JV8
JV8 is a BRD4 PROTAC degrader with a target Kd of 0.65 μM. JV8 preferentially induces BRD4 degradation in the cytoplasm via the ubiquitin-proteasome system. JV8 exhibits dose-dependent and time-dependent BRD4 degradation activity and is capable of inducing cell apoptosis. JV8 inhibits tumor growth in a dose-dependent manner and induces BRD4 degradation in tumor tissues in vivo. JV8 can be used in research related to various cancers such as breast cancer and pancreatic cancer.
(Pink: BRD4 ligand (HY-78695); Blue: Ligands for E3 Ligase ligand (HY-173435); Black: linker (HY-33366)).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2841716-61-6
- Formule: C50H62ClN9O8S2
- Masse moléculaire:1016.67
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform PROTACs
More
Activité biologique
Description
IC50 & Target
[2]|
BRD4 0.65 μM (Kd) |
In Vitro
JV8 (1-100 nM; 24 h) dose-dependently degrades cytoplasmic and total BRD4 in 4T1 cells via the ubiquitin-proteasome system, with minimal nuclear BRD4 degradation at concentrations up to 100 nM, and induces more apoptosis than JQ1(HY-13030)[1].
JV8 (1-100 nM; 24 h) dose-dependently reduces JQ1-NR fluorescence signals in 4T1 cells, correlating with decreased cytoplasmic BRD4 levels[1].
JV8 binds to purified BRD4 (BD1 and BD2) protein with a Kd of 0.65 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:4T1 cells
-
Concentration:1, 5, 10, 50, 100 nM
-
Incubation Time:24 h
-
Result:Induced dose-dependent decreases in BRD4 levels in total 4T1 cells and cytoplasm, with minimal BRD4 degradation in the nucleus even at 100 nM.
Co-treatment with MG132 (HY-13259) blocked JV8-mediated BRD4 degradation, confirming dependence on the ubiquitin-proteasome system.
In Vivo
JV8 (5-10 mg/kg; i.p.; once every 2 days for a total of 5 administrations) induces dose-dependent tumor suppression in subcutaneous 4T1 tumors of BALB/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (subcutaneous 4T1/HeLa/KPC/Hepa 1-6/CT26 tumor model, tumors grown to ~100-150 mm3 prior to treatment)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; single injection
-
Result:Induced complete degradation of BRD4 protein in subcutaneous 4T1, HeLa, KPC, Hepa 1-6, and CT26 tumors in BALB/c mice.
-
Animal Model:BALB/c (subcutaneous 4T1 tumor model, tumors grown prior to treatment initiation)[1]
-
Dosage:5 mg/kg; 10 mg/kg
-
Administration:i.p.; every other day; 5 total doses
-
Result:Exhibited a dose-dependent tumor suppression effect.
Reduced tumor volume and weight significantly in mice treated with 10 mg/kg compared to controls.
Lowered BRD4 levels in tumors from 10 mg/kg treated mice by approximately 4.11-fold compared to PBS-treated mice.
Caused no significant body weight loss in treated groups.
Chemical Information
-
CAS No. 2841716-61-6
-
Masse moléculaire 1016.67
-
Formule C50H62ClN9O8S2
-
SMILES
O=C(NCCOCCOCCOCC(N[C@H](C(C)(C)C)C(N1[C@H](C(N[C@@H](C)C2=CC=C(C3=C(C)N=CS3)C=C2)=O)C[C@@H](O)C1)=O)=O)C[C@@H]4N=C(C5=CC=C(Cl)C=C5)C6=C(SC(C)=C6C)N7C4=NN=C7C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
JV8 Related Classifications
HY-173433 Related Classifications
Powered by Bioz